Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ming-Lung Yu

Showing results (481-490 of 527) with videos related to

Pageof 53
Sort By:
Hepatology International|June 27, 2026
APASL clinical practice guidelines on the management of chronic hepatitis B infection: a 2026 updateHong You, Rakhi Maiwall, Jing Chen, et al.
Journal of Hepatology|October 8, 2022
Metformin reduces hepatocellular carcinoma incidence after successful antiviral therapy in patients with diabetes and chronic hepatitis C in TaiwanPei-Chien Tsai, Hsing-Tao Kuo, Chao-Hung Hung, et al.
Journal of Gastroenterology and Hepatology|February 24, 2021
Long-term risk of end-stage renal diseases with maintenance dialysis among chronic hepatitis C patients after antiviral therapy in TaiwanMeng-Hsuan Hsieh, Ming-Jong Bair, Pei-Chien Tsai, et al.
Journal of the Formosan Medical Association = Taiwan Yi Zhi|March 1, 2025
Posttreatment FIB-4 score change predicts hepatocellular carcinoma in chronic hepatitis C patients: Findings from the Taiwan hepatitis C registry programHung-Wei Wang, Yu-Syuan Zeng, Chung-Feng Huang, et al.
Open Forum Infectious Diseases|December 30, 2020
Successful Antiviral Therapy Reduces Risk of Schizophrenia Among Chronic Hepatitis C Patients: A Nationwide Real-World Taiwanese Cohort (T-COACH)Pei-Chien Tsai, Chi-Yi Chen, Hsing-Tao Kuo, et al.
The Kaohsiung Journal of Medical Sciences|May 24, 2025
Impact of Hepatitis C Virus Clearance on Cardiovascular Risk: A Real-World Experience From the Nationwide Taiwan Hepatitis C Virus RegistryPing-Jen Hu, Pei-Chien Tsai, Chi-Yi Chen, et al.
Clinical and Molecular Hepatology|April 19, 2024
Metformin and statins reduce hepatocellular carcinoma risk in chronic hepatitis C patients with failed antiviral therapyPei-Chien Tsai, Chung-Feng Huang, Ming-Lun Yeh, et al.
Hepatology International|September 7, 2022
Effectiveness of entecavir vs tenofovir disoproxil fumarate for functional cure of chronic hepatitis B in an international cohortYao-Chun Hsu, Dae Won Jun, Cheng-Yuan Peng, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|April 8, 2026
Updated Global Consensus Recommendations for Risk Stratification, Treatment Initiation, and Response Monitoring in Metabolic Dysfunction-Associated Steatotic Liver DiseaseZobair M Younossi, Markos Kalligeros, Vincent Wai-Sun Wong, et al.
Eclinicalmedicine|August 20, 2025
Impact of metabolic dysfunction on treatment responses to nucleos(t)ide analogues in chronic hepatitis B: a retrospective multi-center REAL-B cohort studyRui Huang, Dae Won Jun, Hidenori Toyoda, et al.
Pageof 53

Showing results (481-490 of 527) with videos related to

Sort By:
Pageof 53
Hepatology International|June 27, 2026
APASL clinical practice guidelines on the management of chronic hepatitis B infection: a 2026 updateHong You, Rakhi Maiwall, Jing Chen, et al.
Journal of Hepatology|October 8, 2022
Metformin reduces hepatocellular carcinoma incidence after successful antiviral therapy in patients with diabetes and chronic hepatitis C in TaiwanPei-Chien Tsai, Hsing-Tao Kuo, Chao-Hung Hung, et al.
Journal of Gastroenterology and Hepatology|February 24, 2021
Long-term risk of end-stage renal diseases with maintenance dialysis among chronic hepatitis C patients after antiviral therapy in TaiwanMeng-Hsuan Hsieh, Ming-Jong Bair, Pei-Chien Tsai, et al.
Journal of the Formosan Medical Association = Taiwan Yi Zhi|March 1, 2025
Posttreatment FIB-4 score change predicts hepatocellular carcinoma in chronic hepatitis C patients: Findings from the Taiwan hepatitis C registry programHung-Wei Wang, Yu-Syuan Zeng, Chung-Feng Huang, et al.
Open Forum Infectious Diseases|December 30, 2020
Successful Antiviral Therapy Reduces Risk of Schizophrenia Among Chronic Hepatitis C Patients: A Nationwide Real-World Taiwanese Cohort (T-COACH)Pei-Chien Tsai, Chi-Yi Chen, Hsing-Tao Kuo, et al.
The Kaohsiung Journal of Medical Sciences|May 24, 2025
Impact of Hepatitis C Virus Clearance on Cardiovascular Risk: A Real-World Experience From the Nationwide Taiwan Hepatitis C Virus RegistryPing-Jen Hu, Pei-Chien Tsai, Chi-Yi Chen, et al.
Clinical and Molecular Hepatology|April 19, 2024
Metformin and statins reduce hepatocellular carcinoma risk in chronic hepatitis C patients with failed antiviral therapyPei-Chien Tsai, Chung-Feng Huang, Ming-Lun Yeh, et al.
Hepatology International|September 7, 2022
Effectiveness of entecavir vs tenofovir disoproxil fumarate for functional cure of chronic hepatitis B in an international cohortYao-Chun Hsu, Dae Won Jun, Cheng-Yuan Peng, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|April 8, 2026
Updated Global Consensus Recommendations for Risk Stratification, Treatment Initiation, and Response Monitoring in Metabolic Dysfunction-Associated Steatotic Liver DiseaseZobair M Younossi, Markos Kalligeros, Vincent Wai-Sun Wong, et al.
Eclinicalmedicine|August 20, 2025
Impact of metabolic dysfunction on treatment responses to nucleos(t)ide analogues in chronic hepatitis B: a retrospective multi-center REAL-B cohort studyRui Huang, Dae Won Jun, Hidenori Toyoda, et al.
Pageof 53